**MicroRNA profile in HBV-induced infection and hepatocellular carcinoma**

Guanyu Wang¹, Fulu Dong²†, Zhiyao Xu³, Sherven Sharma⁴, Xiaotong Hu⁵, Dafang Chen³, Lumin Zhang⁵, Jinping Zhang²* and Qinghua Dong³,6*

**Abstract**

**Background:** MicroRNAs (miRNAs) exhibit essential regulatory functions related to cell growth, apoptosis, development and differentiation. Dysregulated expression of miRNAs is associated with a wide variety of human diseases. As such miRNA signatures are valuable as biomarkers for disease and for making treatment decisions. Hepatitis B virus (HBV) is a major risk factor for hepatocellular carcinoma (HCC). Here we screened for miRNAs in chronic HBV associated HCC.

**Methods:** To determine the miRNAs in HCC occurrence associated with HBV infection, we analyzed global miRNA expression profiles in 12 pairs of HCC and adjacent matched non-HCC tissues from HBV-positive and HBV-negative patients using microarray analyses. The microarray result was validated by real-time PCR in 32 HBV-positive and 24 HBV-negative patient HCC samples. The potential candidate target genes of the miRNAs were predicted by miRWalk software. Genes simultaneously predicted as targets by two or more miRNAs were subjected to GO and KEGG pathway analysis. The miRNA regulatory network analysis was performed using the Ingenuity Pathway Analysis (IPA) software.

**Results:** Eight miRNAs (miR-223, miR-98, miR-15b, miR-199a-5p, miR-19b, miR-451, and miR-101) were involved in HBV-unrelated HCC, 5 miRNAs (miR-98, miR-375, miR-335b, miR-199a-5p, and miR-22) were involved in HBV infection, and 7 miRNAs (miR-150, miR-342-3p, miR-663, miR-20b, miR-92a-3p, miR-376c-3p and miR-92b) were specifically altered in HBV-related HCC. Gene Ontology and KEGG analyses predict that these HBV-related HCC miRNAs are involved in the regulation of: transcription, RNA polymerase II promoter, phosphorylation of proteins through MAPK signaling pathway, focal adhesion, and actin cytoskeleton. IPA analysis also suggest that these miRNAs act on AGO2, TP53, CCND1, and 11 other genes that significantly influence HCC occurrence and HBV infection.

**Conclusion:** Our data indicates that the unique 7 miRNAs expression signature could be involved in the development HBV-related HCC.

**Keywords:** Hepatocellular carcinoma, Hepatitis B virus, microRNA, Regulatory network

**Background**

Hepatocellular carcinoma (HCC) is among the most common of solid cancers with the third highest mortality worldwide [1]. Chronic hepatitis B virus (HBV) infection is a major risk factor for HCC [2]. Studies in literature indicate that several HBV-coded proteins promote malignant transformation in hepatocytes [3, 4]. HBV-related HCC has poor clinical recovery because a curative treatment is still lacking and the high rate of recurrence after treatment [5]. An understanding of the pathogenesis of HBV-associated HCC will provide insights for developing effective therapeutic and/or preventive strategies to combat this highly malignant form of cancer [6].

MicroRNAs (miRNA) constitute a recently discovered class of non-coding RNAs and are known to function in the regulation of gene expression [7, 8]. These molecules regulate the expression of as much as 30% of all
mammalian protein-encoding genes. In addition to their important roles in healthy individuals, many studies have revealed that various miRNAs are involved in human carcinogenesis and other diseases. Consequently, miRNAs are being evaluated as candidates for diagnostic/prognostic biomarkers and predictors of drug response. The abnormal expression of miRNAs through transcriptional/post-transcriptional regulation or imperfect pairing with target messenger RNAs (mRNAs) of genes have been observed in disease processes [9–12]. Several studies have shown that expression of miRNAs is dysregulated in HCC compared to non-tumor liver tissues [13]. For example, miR-122 is involved in liver development, differentiation, homeostasis and metabolic functions. MiR-122 targets CUTL1 and CCNG1, and loss of miR-122 results in blocked differentiation, genomic instability, and inflammation associated with liver disease and HCC [14]. MiR-199 targets hepatocyte growth factor receptor, mammalian target of rapamycin (mTOR), and hypoxia-inducible factor (HIF1α), thereby regulating receptor tyrosine kinase and mTOR activation [15]. MiR-21 targets programmed cell death protein 4 (PDCD4) and phosphatase and tensin homolog (PTEN), thereby modulating apoptosis resistance [16]. There is a paucity of information on miRNAs engaged in HBV-related HCC and the regulatory mechanisms of these miRNAs remain largely unknown.

The present study was undertaken to investigate the expression pattern and possible function of miRNAs to provide insights on molecular mechanisms of HBV-related HCC. Results of this study can be used to provide potential candidate biomarkers for HBV-related HCC detection. By miRNA expression profile, we found that miR-150, miR-342-3p, miR-663, miR-20b, miR-92a-3p, miR-376c-3p, and miR-92b are specifically altered in HBV-related HCC. Gene Ontology (GO) and KEGG analysis suggest that these miRNAs may be involved in transcription regulation, MAPK dependent protein phosphorylation, as well as modulation of focal adhesion and actin cytoskeleton. IPA analysis also suggests that these miRNAs act on AGO2, TP53, CCND1, and 11 other genes that are implicated in the occurrence of HCC and HBV infection.

**Methods**

**Patients and samples**

Tumor and paired adjacent non-tumor tissue samples were obtained from 56 liver cancer patients undergoing primary tumor resection at the Sir Run Run Shaw Hospital of Zhejiang University from February 2011 to May 2015. Patients who received pre-operative chemotherapy were excluded. Among the 56 patients, 32 patients were HBV-positive, and 24 patients were HBV-negative. This study was performed in strict accordance with the recommendations from the Guide for Clinical Research provided by Sir Run Run Shaw Hospital, Zhejiang University. The protocol was approved and monitored by the Ethics Committee of Sir Run Run Shaw Hospital, Zhejiang University. Signed informed consent was obtained from each patient. The biopsies were snap-frozen in liquid nitrogen and stored at −80°C until use.

**Microarray analysis**

Microarray assay was started with 2 to 5 μg total RNA sample and performed using a service provider (LC Sciences, http://lcsciences.com/documents/microrna_faq.pdf). Data were analyzed by first subtracting the background and then normalizing the signals using a LOWESS filter (Locally-weighted Regression). For two color experiments, the ratio of the two sets of detected signals (log2 transformed, balanced) and p-values of the t-test were calculated; differentially detected signals were those with less than 0.01 p-values.

**Real time PCR**

Total RNA was purified with TRIzol reagent (Invitrogen) and reverse transcribed using a reverse transcription system (Promega, Madison, WI, USA), according to the manufacturer’s instructions. After polyadenylation, reverse transcription was performed in a 20 μl reaction volume. The reaction was incubated at 42°C for 15 min, and then terminated by heating at 95°C for 5 min. Real-time PCR was performed using FastStart Universal SYBR Green Master (Roche Diagnostics, Rotkreuz, Switzerland), and results analyzed with Eppendorf Real-Time Detection System (Eppendorf, Hauppauge, NY). The primer pairs used for miRNAs are shown in Additional file 1: Table S3. PCR amplification parameters were as follows: 95°C for 5 min, followed by 40 cycles with each cycle at 95°C for 15 s, 60°C for 30 s and 72°C for 30 s. Relative expression levels were calculated using the formula 2^((ΔΔCt)) [17]. The miRNA levels were normalized by actin housekeeping gene.

**Cluster analysis**

Unsupervised hierarchical clustering was carried out using Cluster 3.0 according to methods described previously [18, 19]. Heat maps were generated in Java Treeview, the relative expression of each gene was described as the log10(ratio).

**Analysis of differentially expressed miRNAs**

Differentially expressed miRNAs were analyzed using the significance analysis of microarrays (SAM) program according to methods described previously [18]. The target genes of selected miRNAs were predicted and analyzed by mirWalk, GO and pathway analysis.
Results
HBV-infection induced global changes in miRNA expression
To evaluate the effect of HBV infection on the change in expression of miRNAs, 12 pairs of samples from HCC and non-tumor tissues (including 6 HBV-positive HCC and 6 HBV-negative HCC and their non-tumor tissues) were collected. The extracted RNAs were evaluated to detect the expression of miRNAs. Using ANOVA to screen the differential expression of miRNAs at \( P \)-value \( \leq 0.01 \), fold change \( \geq 2 \) or \( \leq 0.5 \), 225 miRNAs were detected (Additional file 1: Figure S1). This finding suggests that HBV infection may indeed affect the expression of miRNAs in liver cells, and the changes in miRNA expression may result in specific inflammation and tumorigenesis.

To examine the reliability of the array data, we selected 5 miRNAs to confirm their expression in HCC or non-tumor tissues from HBV-positive and HBV-negative patients by using qPCR. The results of qPCR were consistent with microarray data (Fig. 1).

miRNAs are involved in the HBV infection
To determine whether miRNAs are involved in HBV infection, we compared the expressions of miRNAs between HBV-positive and HBV-negative non-tumor tissues. T-test analysis showed that 10 miRNAs were up-regulated and 15 miRNAs were down-regulated in HBV-positive non-tumor tissues compared with those in HBV-negative non-tumor tissues (Additional file 1: Table S1), thereby suggesting the possible role of these miRNAs in HBV infection. MiRNAs selected at fold change > 5 are noted as effective. Five miRNAs (miR-98, miR-375, miR-335, miR-199a-5p, and miR-22) matched the criterion.

The process of selecting predicted target genes that will undergo GO and KEGG pathway analysis was performed as previously described (Fig. 2). GO analysis showed that the most significant biological processes for miR-98, miR-375, and miR-335 include positive regulation of transcription from RNA polymerase II promoter, regulation of transcription, DNA-dependent and ubiquitin-dependent protein catabolism, platelet-derived growth factor receptor...
signaling pathway, embryonic hindgut morphogenesis (Fig. 3a). In the same way, the processes targeted by miR-199a-5p and miR-22 were cellular response to starvation, fructose 2, 6-bisphosphate metabolism, central nervous system projection neuron axon genesis, neuron migration, and dendrite morphogenesis (Fig. 3b).

KEGG pathway analysis showed that the predicted target genes related to miR-98, miR-375, and miR-335 were involved in cytokine-cytokine receptor interaction, calcium signaling pathway, glycan structures - biosynthesis 1, melanoma, and Wnt signaling pathway (Fig. 3c), whereas the predicted target genes of miR-199a-5p and miR-22 were related to MAPK signaling pathway, chronic myeloid leukemia, melanogenesis, insulin signaling pathway, and prostate cancer (Fig. 3d).

HBV-infection alters the expression of miRNAs specifically involved in the carcinogenesis of HCC

To determine which miRNAs specifically function in HBV-induced HCC, we first hypothesized that these pivotal miRNAs should be up-regulated or down-regulated after HBV infection and continually function during carcinogenesis. Hence, miRNAs that were either up-regulated or down-regulated after HBV infection...
were determined by comparing HBV-negative non-tumor tissues and HBV-positive non-tumor tissues (Additional file 1: Table S1). MiRNAs that were up- or down-regulated at fold change >2 in HBV-positive HCC tissues were selected by comparing HBV-positive non-tumor tissues and HBV-positive tumors (Table 1). After compared the expression of miRNAs in HBV-negative non-tumor tissues, HBV-positive non-tumor tissues, HBV-negative tumor tissues and HBV-positive tumor tissues, we selected 12 miRNAs exhibited consistently altered expression levels during HBV infection to HBV-related HCC. Among these 12 miRNAs, 5 were consistently up-regulated and 7 were consistently down-regulated. The identity of the 12 miRNAs is as follows: miR-21, miR-20b, miR-92a-3p, miR-92b, miR-376c-3p, miR-150, miR-451, miR-101, miR-424, miR-342-3p, miR-122a, and miR-663. Results demonstrated that these 12 miRNAs played a regulatory role in the occurrence of HCC caused by HBV infection. By comparing HBV-negative non-tumor tissues and HBV-negative tumors, we found that the expressions of 11 miRNAs increased, whereas the expressions of 15 miRNAs decreased (Additional file 1: Table S2). To obtain miRNAs that are specific to HBV-induced HCC, we deduce the same miRNAs that function in HBV-unrelated HCC. Finally, we found 7 HBV-related miRNAs that are involved in HCC occurrence after removing 5 non-specific miRNAs (miR-21, miR-451, miR-101, miR-424, and miR-122a). Ultimately, miR-20b, miR-92a-3p, miR-92b, miR-376c-3p, miR-150, miR-342-3p, and miR-663 were selected. These miRNAs, 4 up-regulated and 3 down-regulated, are specifically involved in HBV-induced HCC. Genes that are targeted by the 7 selected miRNAs may be involved in critical functional pathways that lead to HBV-related HCC.

**Functional analysis of miRNAs in HBV-induced HCC**

The functions of the 7 miRNAs with possible specific involvement in HBV-induced HCC were extensively analyzed. miRWalk software was used to predict the target genes of these miRNAs. Genes predicted simultaneously as target genes by two or more miRNAs were selected and subjected to GO and KEGG pathway analysis as previously described (Fig. 4). Results showed that the most significant biological processes targeted by at least two of various miRNAs (miR-20b, miR-92a-3p, miR-92b, and miR-376c-3p) were regulation of transcription, DNA-dependent positive regulation of transcription from RNA polymerase II promoter, protein amino acid phosphorylation, and negative regulation of transcription from RNA polymerase II promoter, regulation of transcription, DNA-dependent protein amino acid phosphorylation, and negative regulation of transcription from RNA polymerase II promoter (Fig. 5b). The up-regulated and down-regulated miRNAs (miR-20b, miR-92a-3p, miR-92b, miR-376c-3p, miR-150, miR-342-3p, and miR-663) may be involved in the regulation of transcription, DNA-dependent positive regulation of transcription from RNA polymerase II promoter, protein amino acid phosphorylation, and negative regulation of transcription from RNA polymerase II promoter.

Pathway analysis showed that the predicted target genes related to miR-20b, miR-92a-3p, miR-92b, and miR-376c-3p were involved in regulation of actin cytoskeleton, focal adhesion, MAPK signaling pathway, calcium signaling pathway, and axon guidance (Fig. 5c). The predicted target genes of miR-150, miR-342-3p, and miR-663 were related to MAPK signaling pathway, cytokine-cytokine receptor interaction, focal adhesion, insulin signaling pathway, and regulation of actin cytoskeleton (Fig. 5d). These collective findings suggest that miRNAs may serve functions in HBV-induced HCC through MAPK signaling pathway, focal adhesion, and regulation of actin cytoskeleton.

The ingenuity pathway analysis (IPA) is able to identify published direct binding partners, transcriptional regulators, and translational regulators of specific molecules. The functional pathways regulated by all the selected miRNAs can manifest the co-regulated relationships of these miRNAs. In our study, a network that includes 6 of 7 selected miRNAs (miR-150, miR-342-3p, miR-20b, miR-92, miR-368, and miR-92b) was shown based on accepted databases of molecular interactions reported in the literature using IPA (Fig. 6). These 6 miRNAs act on AG02, TP53, CCND1, and other 11 genes that play important roles in HCC occurrence and HBV infection.

**Discussion**

HBV infection is a major health problem that leads to a significant rise in mortality and is reported to be closely related to HCC [20]. HBV contains four open reading frames (ORFs), namely, S, P, X, and pre C, whose products are HBsAg, HBeAg, HBsAg, and HBx, respectively [21]. Expression of HBV proteins was previously demonstrated to modulate the expression of some genes that likely contribute to the pathogenesis of HCC [3, 4]. Especially HBx plays a critical role in HBV-related HCC [21]. HBx can stop cell death mediated by p53, Fas, and transforming growth factor-β [22, 23], thereby implying the importance of regulation of apoptosis in the occurrence of HBV-related HCC. One report has shown that down-regulating the expressions of HBsAg, HBeAg, p21, and Rb proteins in HCC increases the propensity for HCC occurrence, indicating that these proteins are
tumor suppressors and would influence the course of cell cycle and apoptosis [24]. All of the above information implied that HBV infection could affect cell cycle and survival and could eventually lead to HCC.

In our IPA results, the 6 selected miRNAs (miR-150, miR-342-3p, miR-20b, miR-92a-3p, miR-92b, and miR-376c-3p) are shown to comprise a network which linked themselves among AGO2, DICER1, BCL2L11, CCND1, CCND2, CCNE1, CDK7, E2F1, E2F3, TP53, and four other genes (Fig. 6). Argonaute RISC catalytic component 2 (AGO2) and dicer 1 (DICER1) were highlighted. AGO2 plays a role for RNA interference in regulating the chromatin structure. AGO2 may interact with dicer1 and play a role in short-interfering-RNA-mediated gene silencing. Previous reports have indicated that HBsAg and HBcAg co-localized with AGO2. Moreover, HBV-specific miRNAs, together with AGO2, play a role in the viral life cycle [25]. So far, no HBV-encoded miRNA has been identified [26]. Other genes shown in the IPA network were involved in regulation of cellular regulatory pathway. Thus, we can speculate that cellular miRNAs may function in HBV-induced HCC either by targeting cellular transcription factors required for HCC occurrence or by directly binding to HBV transcripts to affect HBV gene expression.

### Table 1 Differentially expressed microRNAs in HCC versus adjacent non-tumor tissues from HBV-positive patients

| Reporter name | p-value | HBV + tumor Mean | StDev | HBV + non-tumor Mean | StDev | Fold change |
|---------------|---------|------------------|-------|----------------------|-------|-------------|
| miR-368       | 1.01E-12| 3188             | 99    | 109                  | 7     | 29.17       |
| miR-487b      | 5.33E-15| 2983             | 183   | 106                  | 6     | 28.17       |
| miR-127       | 6.02E-09| 5319             | 145   | 218                  | 20    | 24.36       |
| miR-19b       | 1.33E-15| 18,147           | 452   | 2382                 | 83    | 7.62        |
| miR-22        | 5.79E-08| 3234             | 51    | 574                  | 47    | 5.64        |
| miR-181a      | 1.86E-09| 5512             | 209   | 1519                 | 105   | 3.63        |
| miR-25        | 7.89E-10| 8586             | 512   | 3491                 | 201   | 2.46        |
| miR-191       | 1.54E-10| 8562             | 267   | 3521                 | 155   | 2.43        |
| miR-125b      | 1.86E-10| 13,712           | 365   | 5849                 | 270   | 2.34        |
| miR-125a      | 1.04E-08| 5357             | 389   | 2408                 | 161   | 2.22        |
| miR-27a       | 3.79E-11| 12,665           | 409   | 5814                 | 233   | 2.18        |
| miR-24        | 1.03E-05| 10,905           | 996   | 5138                 | 161   | 2.12        |
| miR-143       | 8.95E-10| 8383             | 426   | 4040                 | 186   | 2.08        |
| miR-638       | 1.44E-10| 22,023           | 780   | 10,794               | 454   | 2.04        |
| miR-103       | 1.05E-09| 7394             | 303   | 3661                 | 199   | 2.02        |
| miR-15a       | 6.98E-09| 2089             | 79    | 4434                 | 275   | –2.13       |
| miR-195       | 3.82E-10| 7697             | 323   | 17,122               | 921   | –2.22       |
| miR-146a      | 1.36E-09| 4030             | 253   | 10,074               | 647   | –2.50       |
| miR-361       | 3.78E-09| 1933             | 156   | 6058                 | 349   | –3.13       |
| miR-101       | 2.44E-09| 964              | 97    | 3290                 | 267   | –3.45       |
| miR-671       | 6.21E-11| 1481             | 93    | 6074                 | 245   | –4.17       |
| miR-152       | 5.71E-10| 1118             | 42    | 4799                 | 315   | –4.35       |
| miR-146b      | 1.13E-10| 2357             | 230   | 11,701               | 826   | –5.00       |
| miR-451       | 3.67E-11| 1985             | 90    | 10,252               | 700   | –5.26       |
| miR-98        | 2.16E-08| 1009             | 180   | 5705                 | 612   | –5.56       |
| miR-375       | 1.11E-08| 623              | 61    | 4157                 | 160   | –6.67       |
| miR-768-3p    | 4.00E-15| 837              | 27    | 7214                 | 281   | –8.33       |
| miR-10a       | 2.96E-11| 351              | 41    | 4116                 | 410   | –11.11      |
| miR-768-5p    | 2.36E-11| 611              | 64    | 9400                 | 606   | –14.29      |
| miR-335       | 1.57E-07| 261              | 72    | 4499                 | 692   | –16.67      |
| miR-29c       | 2.08E-10| 416              | 67    | 7547                 | 806   | –16.67      |
| miR-155       | 6.00E-12| 310              | 19    | 5898                 | 589   | –20.00      |
Many functional pathways are reportedly regulated during HBV infection. The deregulation of signaling pathways includes MAPKs, p53, Wnt/β-catenin, transforming growth factor β (TGF β), cytokines, and Jak-STAT [27, 28], and results to down-regulation of tumor suppressor gene expression and/or up-regulation of oncogene expression [29]. Coincidently, the pathway analysis results showed that the 7 miRNAs selected through the process were closely involved in MAPK signaling pathway, TGF-beta signaling pathway, cytokine-cytokine receptor interaction, wnt signaling pathway, Jak-STAT signaling pathway, and apoptosis (Fig. 5c, d). Thus, HBV infection may induce HCC mainly by acting on these miRNAs to influence liver cell states.

Products of HBV contribute to HBV-associated HCC; some of these can prompt cell cycle regulatory pathways [30]. For example, studies demonstrated that HBx, a product of HBV, triggered the occurrence of HCC by decreasing the levels of cell cycle proteins that prevent

---

**Fig. 4** Venn diagram analysis of the relationship among target genes predicted by differentially expressed miRNAs which are involved in HBV-induced HCC. *a* Relationship among target genes predicted by miR-20b, miR-92a-3p, miR-92b, and miR-376c-3p. *b* Relationship among target genes predicted by miR-150, miR-342-3p, and miR-663

**Fig. 5** GO and pathway analysis result of the target genes predicted by differentially expressed miRNAs which are involved in HBV-induced HCC. \(-\log_{10}(P)\) indicates the GO score related to genes in the biological process by P-value. *a* Main biological processes influenced by genes targeted by two or more miRNAs from miR-20b, miR-92a-3p, miR-92b, and miR-376c-3p. *b* Main biological processes influenced by genes targeted by two or more miRNAs from miR-150, miR-342-3p, and miR-663. *c* Main pathways influenced by genes targeted by two or more miRNAs from miR-20b, miR-92a-3p, miR-92b, and miR-376c-3p. *d* Main pathways influenced by genes targeted by two or more miRNAs from miR-19b, miR-101, and miR-199a-5p
progression into G1 phase and increasing the levels of cell cycle proteins active in the G1 phase [31]. Cell cycle regulation plays an important role in HBV-induced HCC. In our study, genes of cell cycle proteins, namely, cyclin D1 (CCND1), cyclin D2 (CCND2), cyclin E1 (CCNE1), cyclin-dependent kinase 7 (CDK7), transcription factor 1 (E2F1), transcription factor 3 (E2F3), and tumor protein p53 (TP53) appeared in the IPA network (Fig. 6). The proteins encoded by these genes are obviously involved in cell cycle. Cyclin D1, cyclin D2 and cyclin E1 belong to the highly conserved cyclin family. Among these proteins, cyclin D1 and cyclin D2 form a complex with and function as a regulatory subunit of CDK4 or CDK6, whose activity is required for cell cycle G1/S transition. In addition, cyclin E1 functions with CDK2, whose activity is also necessary in G1/S transition [32]. Thus, mutations, amplification, and overexpression of these genes are frequently observed in HBV-related HCC [33]. Cyclin-dependent kinase 7 serves as a direct link between the regulation of transcription and the cell cycle [34]. E2F1 and E2F3 are members of the E2F family, their target genes function in DNA replication and repair, cell cycle regulation, cell cycle checkpoint, cell death, differentiation. E2F transcription factors are key targets of the retinoblastoma (Rb) tumor suppressor [35]. Previous research indicated that P53 was the most frequently altered pathway in HBV-related HCC, and TP53 was associated with shorter survival only in HBV-related HCC [36]. Coincidently, our target gene analysis showed that all the 4 up-regulated miRNAs (miR-20b, miR-92a-3p, miR-92b, and miR-376c-3p) target TP53, cyclin-dependent kinase inhibitor 1A (CDKN1A) and cyclin-dependent kinase inhibitor 2A (CDKN2A). Our study verified that the expression of TP53 and CDKN1A were decreased in HBV positive tumors compared with HBV positive non-tumor tissues (Additional file 1: Figure S2). TP53 is a classical suppressor gene that is related to cell cycle and accumulation of genetic changes. The proteins encoded by CDKN1A and CDKN2A can inhibit the activity of cyclin-CDK and function as tumor suppressors to control cell cycle in HBV-related HCC [37, 38]. In addition, all down-regulated miRNAs (miR-150, miR-342-3p, and miR-663) target baculoviral IAP repeat containing 5 (BIRC5), CCND1, and protein tyrosine kinase 2 (PTK2). The expression of these three genes was increased in HBV positive tumors compared with HBV positive non-tumor tissues (Additional file 1: Figure S2). The product of PTK2 acts on cell cycle by regulating the tumor suppressor p53 [39]. Based on these results, aberrant regulation

![Fig. 6 Results of IPA analysis of the target genes predicted by differentially expressed miRNAs involved in HBV-induced HCC. IPA-obtained network showing the relationships among 6 co-regulated miRNAs (miR-150, miR-342-3p, miR-92a-3p, miR-92b, and miR-376c-3p)](image-url)
Bcl-2 lower expression of miR-150 and miR-342-3p up-regulated regulation in HBV-related HCC [37, 39, 47]. These genes were reportedly closely involved in apoptosis increased in HBV positive tumors compared with HBV negative non-tumor tissues (Additional file 1: Figure S2A). The expression of these three genes was decreased in HBV positive tumors compared with HBV positive non-tumor tissues (Additional file 1: Figure S2A). All down-regulated miRNAs (miR-150, miR-342-3p, and miR-663) target B-cell lymphoma/leukemia 2 (BCL2), BIRC5 and PTK2. The expression of these three genes was increased in HBV positive tumors compared with HBV positive non-tumor tissues (Additional file 1: Figure S2B). These genes were reportedly closely involved in apoptosis regulation in HBV-related HCC [37, 39, 47–52]. Moreover, lower expression of miR-150 and miR-342-3p up-regulated Bcl-2–associated X protein and CASP8 and FADD-like apoptosis regulator (CFLAR), which have apoptotic activities [49, 53]. All these outcomes imply the importance of apoptosis regulation by miRNAs in HBV-related HCC.

From aforementioned results, we can speculate that a co-regulation exists among the 7 selected miRNAs, thereby promoting HBV-related HCC. First, 6 selected miRNAs comprised a network; these miRNAs linked themselves among AGO2, DICER1, BCL2L11, CCND1, CCND2, CCNE1, CDK7, E2F1, E2F3, TP53, and four other genes. AGO2 and DICER2, together with miRNAs and HBV products, affect viral life cycle. Other genes, however, mainly function in cellular regulatory pathways. So far, no HBV-encoded miRNA has been identified. Thus, we speculate that cellular miRNAs may function in HBV-induced HCC at the transcription level either by targeting cellular transcription factors required for HCC occurrence or by a directly binding to HBV transcripts to affect HBV gene expression. Furthermore, we found that all 7 HBV-specific miRNAs participate in cell cycle and apoptosis by regulating various genes that code for cell cycle and apoptosis regulators. All these miRNAs act together to regulate a variety of physiological functions, which ultimately lead to HCC. We may use these 7 miRNAs as possible biomarkers that can be applied to HBV-induced HCC detection, early intervention, and recurrence. However, all of these predictions are a good starting point for the involvement of miRNAs in HBV-related HCC, and the exact functions of the miRNAs identified in this article need experimental verification.

Conclusions

Aberrations in miRNA expression are correlated to cancer progression. In this study, we analyzed global miRNA expression profiles in HCC and adjacent matched non-HCC tissues from HBV-positive and HBV-negative patients. Our data indicates that the unique 7 miRNAs (miR-150, miR-342-3p, miR-663, miR-20b, miR-92a-3p, miR-376c-3p and miR-92b) expression signature could be involved in the development of HBV-related HCC, suggesting interesting potential novel therapeutic options. However, further functional studies are needed to clarify the role of these miRNAs in HBV-related HCC.

Additional file

Additional file 1: Figure S1. The expression profiles of global miRNAs in HCC and adjacent non-tumor tissues of HBV-positive and HBV-negative patients. A heatmap of global miRNAs in HCC and non-tumor tissues obtained from 12 people (6 tumor tissues and 6 adjacent non-tumor tissues from 6 HBV-positive HCC patients, 6 tumor tissues and 6 adjacent non-tumor tissues from 6 non-HBV-negative HCC patients). TN = tumors of HBV-negative patients, PN = adjacent non-tumor tissues of HBV-negative patients, TP = tumors of HBV-positive patients, PP = adjacent non-tumor tissues of HBV-positive patients. Figure S2. Expression of partial target genes predicted by differentially expressed miRNAs. (A) Expression of gene TP53, CDKN1A, ERK and PTEN in 32 pairs of HBV positive adjacent non-tumor and tumor tissues. (B) Expression of gene BIRC5, CCND1, PTK2 and BCL2 in 32 pairs of HBV positive adjacent non-tumor and tumor tissues. **P < 0.01, ***P < 0.001, ****P < 0.0001. Table S1. Differentially expressed microRNAs in HCC versus normal tissues from HBV-negative patients. Table S2. Differentially expressed microRNAs in normal tissues from HBV-positive versus HBV-negative patients. Table S3. Primers used in real time PCRs for detecting microRNAs expression. (DOC 610 kb)

Abbreviation

AGO2: Argonaute RISC catalytic component 2; BCL2: B-cell lymphoma/leukemia 2; BCL2L11: B-cell lymphoma 2-like 11; BID: BH3-interacting domain; BRCS: Baculoviral IAP repeat containing 5; CCND1: Cyclin D1; CCND2: Cyclin D2; CCNE1: Cyclin E1; CDK2: Cyclin-dependent kinase 2; CDKN1A: Cyclin-dependent kinase inhibitor 1A; CDKN2A: Cyclin-dependent kinase inhibitor 2A; CFLAR: CASP8 and FADD-like apoptosis regulator; E2F1: Transcription factor 1; E2F3: Transcription factor 3; FADD: Fas-associated protein with death domain; GO: Gene Ontology; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HIF-1α: Hypoxia-inducible factor; IPA: Ingenuity Pathway Analysis; miRNA: microRNA; mRNAs: messenger RNAs; mTOR: mammalian target of rapamycin; ORFs: Open reading frames; PDCD4: Programmed cell death protein 4; PTEN: Phosphatase and tensin homolog; PTK2: Protein tyrosine kinase 2; TGF β: Transforming growth factor β; TP53: Tumor protein p53

Acknowledgements

We are grateful to Jiali Yu for her help of data input.
Funding
This work was supported by the National Natural Science Foundation of China (No. 81272493 to QD, 81472213 to GW, 31770939, 81471526, 91442110 to JP, 81300553 to FD), the Science Technology Department of Zhejiang Province (No. 2015C33314 and No.2015C37112), the 45th Scientific Research Foundation for Returned Scholars by Ministry of Education of China, the Priority Academic Program Development of Jiangsu Higher Education Institution, Jiangsu Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Sciences of Soochow University, intramural research funding to JZ (No.Q413401810) from Soochow University, Natural Science Foundation of Jiangsu Province to JZ (No.BK2012167), Key University Science Research Project of Jiangsu Province to JZ (No.13KJA310004). Funding bodies did not have any influence in the design of the study and collection, analysis and interpretation of data or in writing the manuscript.

Availability of data and materials
The datasets generated and/or analysed during the current study are available in the ArrayExpress repository (E-MTAB-4809), [http://www.ebi.ac.uk/arrayexpress/help/how_to_search_private_data.html].

Authors’ contributions
GYW, ZYX, XTH and LMZ collected 56 patients.

Ethics approval and consent to participate
This study was performed in strict accordance with the recommendations from the Guide for Clinical Research provided by Sir Run Run Shaw Hospital, Zhejiang University. The protocol was approved and monitored by the Ethics Committee of Sir Run Run Shaw Hospital, Zhejiang University. Signed informed consent was obtained from each patient.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. 2Institutes of Biology and Medical Sciences, Soochow University, Soochow, Jiangsu, China. 3Key Lab of Biomedical Research Center, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. 4David Geffen School of Medicine at UCLA, and the Department of Veterans Affairs, Los Angeles, CA, USA. 5Key Laboratory of Biotechnology of Zhejiang Province, Hangzhou, Zhejiang, China. 6Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Hangzhou, China.

Received: 2 June 2016 Accepted: 22 November 2017
Published online: 01 December 2017

References
1. Kerr TA, Korenblit KM, Davidson NO. MicroRNAs and liver disease. Transl Res. 2011;157(4):241–52.
2. Motavaf M, Safavi S, Safaifi Jourshari M, Alavian SM. Hepatitis B virus-induced hepatocellular carcinoma: the role of the virus x protein. Acta Virol. 2013;57(4):389–96.
3. Su JI, Wang HC, Wu HC, Huang WY. Ground glass hepatocytes contain pre-S mutants and represent preneoplastic lesions in chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2008;23(8 Pt 1):1169–74.
4. Soussan P, Garreau F, Zylberberg H, Ferray C, Brecht C, Kremsdorf D. In vivo expression of a new hepatitis B virus protein encoded by a spliced RNA. J Clin Invest. 2000;105(1):55–60.
5. El-Seraq HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology. 2001;33(1):62–5.
6. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene. 2006;25(17):2537–45.
7. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(3):843–54.
8. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell. 1992;75(5):655–62.
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;126(2):265–73.
10. Harfe BD. MicroRNAs in vertebrate development. Curr Opin Genet Dev. 2005;15(4):410–5.
11. Bartel DP, Chen CZ. MicroRNAs: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet. 2004;5(5):369–400.
12. Rajewsky N. microRNA target predictions in animals. Nat Genet. 2006;38(Suppl):S8–13.
13. Negrini M, Gramantieri L, Sabbioni S, Croce CM. microRNA involvement in hepatocellular carcinoma. Anti Cancer Agents Med Chem. 2011;11(6):500–21.
14. Hsu S, Wang B, Kota J, Yu J, Costinean S, Kutty H, et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of mir-122 in liver. J Clin Invest. 2012;122(8):2871–83.
15. Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi Gl, et al. MR-199a-3p regulates mTOR and c-met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2010;70:1894–93.
16. Callegari E, Elamin BK, Sabbioni S, Gramantieri L, Negrini M. Role of microRNAs in hepatocellular carcinoma: a clinical perspective. Oncotarget. 2013;6:1167–78.
17. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–8.
18. Dong F, Zhang Y, Xia F, Yang Y, Xiong S, Jin L, Zhang J. Genome-wide miRNA profiling of villus and decidua of recurrent spontaneous abortion patients. Reproduction. 2014;148(1):33–41.
19. de Heon MJ, Inoto S, Nolan J, Myson S. Open source clustering software. Bioinformatics. 2004;20(9):1453–4.
20. Ayub A, Ashfaq UA, Haque A. HBV induced HCC: major risk factors from genetic to molecular level. Biomed Res Int. 2013;2013:810461.
21. Hwang GY, Lin CY, Huang LM, Wang YH, Wang JC, Hsu CT, et al. Detection of the hepatitis B virus X protein (HBx) antigen and anti-HBx antibodies in cases of human hepatocellular carcinoma. J Clin Microbiol. 2004;42(12):5598–603.
22. Qadri I, Conaway JW, Conaway RC, Schaack J, Siddiqui A. Hepatitis B virus reverse transcriptase: cofactors of DNA initiation. J Biol Chem. 1998;273(36):22783–90.
23. Elmore LW, Hancock AR, Chang SF, Wang XW, Chang S, Callahan CP, et al. Hepatitis B virus X protein and ps3 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci U S A. 1997;94(26):14707–12.
24. Liu K, Lei XZ, Zhao LS, Tang H, Liu L, Feng P, et al. Tissue microarray for high-throughput analysis of gene expression profiles in hepatocellular carcinoma. World J Gastroenterol. 2005;11(9):1369–72.
25. Hayes CN, Akamatsu S, Duan LX, Sun BS, Feitelson MA. Hepatitis B virus-specific miRNAs and Argonaute2 play a role in the viral life cycle. PLoS One. 2012;7(10):e47490.
26. Liu WH, Yeh SH, Chen PJ. Role of microRNAs in hepatitis B virus replication and pathogenesis. Biochim Biophys Acta. 2011;1809(11):12768–85.
27. Pan J, Duan LX, Sun BS, Feitelson MA. Hepatitis B virus X protein protects against anti-Fas-mediated apoptosis in human liver cells by inducing NF-κappaB. J Gen Virol. 2001;82(Pt 1):121–32.
28. Yen CJ, Lin YJ, Yen CS, Tsai HW, Tsai TF, Chang KY, et al. Hepatitis B virus X protein upregulates mTOR signaling through IKKβ to increase cell proliferation and VEGF production in hepatocellular carcinoma. PLoS One. 2012;7(7):e41931.
29. Yamazaki K, Masugi Y, Sakamoto M. Molecular pathogenesis of hepatocellular carcinoma: altering transforming growth factor-β signaling in hepatocarcinogenesis. Dig Dis. 2011;29(3):284–8.
30. Cheong JH, Yi M, Lin Y, Murakami S. Human RPS5, a subunit shared by eukaryotic nuclear RNA polymerases, binds hepatitis B virus X protein and may play a role in X transactivation. EMBO J. 1995;14(1):143–50.
31. Hung CH, Chiu YC, Chen CH, Hu TH. MicroRNAs in hepatocellular carcinoma: carcinogenesis, progression, and therapeutic target. Biomed Res Int. 2014;2014:86407.
32. Jiang W, Huang H, Ding L, Zhu P, Saiyin H, Ji G, et al. Regulation of cell cycle of hepatocellular carcinoma by NFκB through modulation of cyclin E1 mRNA stability. Oncogene. 2015;34(34):4460–70.
33. Park TJ, Chun JY, Bae JS, Park BL, Cheong HS, Lee HS, et al. CCND2 polymorphisms associated with clearance of HBV infection. J Hum Genet. 2010;55(7):416–20.
34. Kelso TW, Baumgart K, Eickhoff J, Albert T, Antrecht C, Lemcke S, et al. Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells. Mol Cell Biol. 2014;34(19):3675–88.
35. Díck FA, Rubin SM. Molecular mechanisms underlying RB protein function. Nat Rev Mol Cell Biol. 2013;14(9):297–306.
36. Amaddeo G, Cao Q, Ladeiro Y, Imbeaud S, Nault JC, Jaoui D, et al. Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas. Gut. 2015;64(5):820–9.
37. Wu ZI, Zhu Y, Huang DR, Wang ZQ. Constructing the HBV-human protein interaction network to understand the relationship between HBV and hepatocellular carcinoma. J Exp Clin Cancer Res. 2010;29:146.
38. Csepregi A, Ebert MP, Röcken C, Schneider-Stock R, Hoffmann J, Schulz HU, et al. Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma. BMC Cancer. 2010;10:317.
39. Berzsenyi MD, Roberts SK, Beard MR. Genomics of hepatitis B and C infections: diagnostic and therapeutic applications of microarray profiling. Antivir Ther. 2006;11(5):541–52.
40. Li N, Zhang J, Jiao T, Li Z, Peng J, Cui Z, et al. Hepatitis B virus inhibits apoptosis of hepatoma cells by sponging the MicroRNA 15a/16 cluster. J Virol. 2013;87(24):13370–8.
41. Li C, Wang YK, Wang CY, Du L, Zhang XH, Dong GF. Correlation of hepatitis B virus X antigen expression with liver cell apoptosis. Zhonghua Gan Zang Bing Za Zhi. 2013;21(4):252–6.
42. Knoll S, Forst K, Thomas S, Villanueva Baselga S, Stoll A, Schaefer S, et al. Dissection of cell context-dependent interactions between HBx and p53 family members in regulation of apoptosis: a role for HBV-induced HCC. Cell Cycle. 2011;10(20):3554–65.
43. Morales LD, Casillas Pavón EA, Shin JW, García A, Capetillo M, Kim DJ, et al. Protein tyrosine phosphatases PTP-1B, SHP-2, and PTEN facilitate Rb/E2F-associated apoptotic signaling. PLoS One. 2014;9(5):e97104.
44. Rotgers E, Rivero-Müller A, Nurmio M, Parvinen M, Guillou F, Huhtaniemi I, et al. Retinoblastoma protein (RB) interacts with E2F3 to control terminal differentiation of Sertoli cells. Cell Death Dis. 2014;5:e1274.
45. scarfò L, Ghia P. Reprogramming cell death: BCL2 family inhibition in hepatic cell apoptosis. Mol Cancer. 2016;15:94.
46. Kelso TW, Baumgart K, Eickhoff J, Albert T, Antrecht C, Lemcke S, et al. Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas. Gut. 2015;64(5):820–9.
47. Wu ZI, Zhu Y, Huang DR, Wang ZQ. Constructing the HBV-human protein interaction network to understand the relationship between HBV and hepatocellular carcinoma. J Exp Clin Cancer Res. 2010;29:146.
48. Csepregi A, Ebert MP, Röcken C, Schneider-Stock R, Hoffmann J, Schulz HU, et al. Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma. BMC Cancer. 2010;10:317.
49. Berzsenyi MD, Roberts SK, Beard MR. Genomics of hepatitis B and C infections: diagnostic and therapeutic applications of microarray profiling. Antivir Ther. 2006;11(5):541–52.
50. Li N, Zhang J, Jiao T, Li Z, Peng J, Cui Z, et al. Hepatitis B virus inhibits apoptosis of hepatoma cells by sponging the MicroRNA 15a/16 cluster. J Virol. 2013;87(24):13370–8.
51. Li C, Wang YK, Wang CY, Du L, Zhang XH, Dong GF. Correlation of hepatitis B virus X antigen expression with liver cell apoptosis. Zhonghua Gan Zang Bing Za Zhi. 2013;21(4):252–6.
52. Knoll S, Forst K, Thomas S, Villanueva Baselga S, Stoll A, Schaefer S, et al. Dissection of cell context-dependent interactions between HBx and p53 family members in regulation of apoptosis: a role for HBV-induced HCC. Cell Cycle. 2011;10(20):3554–65.
53. Morales LD, Casillas Pavón EA, Shin JW, García A, Capetillo M, Kim DJ, et al. Protein tyrosine phosphatases PTP-1B, SHP-2, and PTEN facilitate Rb/E2F-associated apoptotic signaling. PLoS One. 2014;9(5):e97104.
54. Rotgers E, Rivero-Müller A, Nurmio M, Parvinen M, Guillou F, Huhtaniemi I, et al. Retinoblastoma protein (RB) interacts with E2F3 to control terminal differentiation of Sertoli cells. Cell Death Dis. 2014;5:e1274.
55. scarfò L, Ghia P. Reprogramming cell death: BCL2 family inhibition in hematological malignancies. Immunol Lett. 2013;151(1–2):36–9.
56. Nakos M, Wolfier A, Raj K, Kummer JA, Mill P, van Noort M, et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet. 2003;33(3):416–21.
57. Yuan K, Lian Z, Sun B, Clayton MM, Ng IO, Feitelson MA. Role of miR-18a in hepatitis B associated hepatocellular carcinoma. PLoS One. 2012;7(4):e35331.
58. Chen GG, Lai PB, Chan PK, Chak EC, Yip JH, Ho RL, et al. Decreased expression of bid in human hepatocellular carcinoma is related to hepatitis B virus X protein. Eur J Cancer. 2001;37(13):1695–702.
59. Lee CF, Ling QZ, Zhao T, Lee KR. Distinct expression patterns in hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma. World J Gastroenterol. 2008;14(39):6072–7.
60. Hung CH, Teng YN, Wang LH, Su JL, Wang CC, Huang W, et al. Induction of Bcl-2 expression by hepatitis B virus pre-S2 mutant large surface protein resistance to 5-fluorouracil treatment in Huh-7 cells. PLoS One. 2011;6(12):e28977.
61. Wang L, Huang J, Jiang M, Sun L. Survivin (BIRC5) cell cycle computational network in human no-tumor hepatitis/cirrhosis and hepatocellular carcinoma transformation. J Cell Biochem. 2011;112(5):1286–94.
62. Zhang X, Dong N, Yin L, Cai N, Ma H, You J, et al. Hepatitis B virus X protein upregulates survivin expression in hepatoma tissues. J Med Virol. 2005;77(3):374–81.
63. Ali M, Idees M, Ali L, Hussain A, Ur Rehman I, Saleem S, et al. Hepatitis B virus in Pakistan: a systematic review of prevalence, risk factors, awareness status and genotypes. Virol J. 2011;8:102.